AAP
GH icon

Aristotle Atlantic Partners’s Guardant Health GH Stock Holding History

Aristotle Atlantic Partners’s Portfolio GH Stock Details GH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41.2M Sell
445,530
-48,856
-10% -$4.91M 1.93% 15
2025
Q4 		$50.5M Sell
494,386
-429,348
-46% -$38.4M 2.31% 11
2025
Q3 		$57.7M Sell
923,734
-8,222
-0.9% -$447K 1.67% 15
2025
Q2 		$48.5M Sell
931,956
-32,565
-3% -$1.45M 1.48% 19
2025
Q1 		$41.1M Buy
964,521
+112,526
+13% +$4.85M 1.39% 23
2024
Q4 		$26M Sell
851,995
-41,513
-5% -$1.17M 0.82% 32
2024
Q3 		$20.5M Buy
893,508
+144,311
+19% +$4.08M 0.64% 41
2024
Q2 		$21.6M Sell
749,197
-57,698
-7% -$1.34M 0.7% 39
2024
Q1 		$16.6M Sell
806,895
-30,050
-4% -$644K 0.54% 53
2023
Q4 		$22.6M Buy
836,945
+2,849
+0.3% +$74.7K 0.8% 43
2023
Q3 		$24.7M Sell
834,096
-23,472
-3% -$825K 0.99% 36
2023
Q2 		$30.7M Buy
857,568
+237,074
+38% +$6.81M 1.16% 27
2023
Q1 		$14.5M Buy
620,494
+1,723
+0.3% +$49.2K 0.75% 47
2022
Q4 		$16.8M Buy
618,771
+237,627
+62% +$10.9M 0.94% 39
2022
Q3 		$20.5M Buy
381,144
+172,050
+82% +$8.83M 1.25% 25
2022
Q2 		$8.44M Buy
209,094
+3,894
+2% +$193K 0.65% 42
2022
Q1 		$13.6M Buy
205,200
+2,847
+1% +$195K 0.84% 33
2021
Q4 		$20.2M Buy
202,353
+7,423
+4% +$768K 1.17% 29
2021
Q3 		$24.4M Buy
194,930
+2,223
+1% +$264K 1.61% 24
2021
Q2 		$23.9M Buy
192,707
+1,839
+1% +$247K 1.58% 26
2021
Q1 		$29.1M Buy
190,868
+3,462
+2% +$523K 2.13% 15
2020
Q4 		$24.2M Buy
187,406
+2,749
+1% +$316K 1.86% 23
2020
Q3 		$20.6M Buy
184,657
+1,560
+0.9% +$143K 1.82% 23
2020
Q2 		$14.9M Buy
183,097
+35,855
+24% +$2.89M 1.43% 28
2020
Q1 		$10.2M Buy
147,242
+4,058
+3% +$311K 1.57% 28
2019
Q4 		$11.2M Buy
143,184
+100,167
+233% +$7.22M 1.43% 27
2019
Q3 		$2.75M Buy
43,017
+1,011
+2% +$89.1K 0.79% 26
2019
Q2 		$3.63M Buy
42,006
+1,851
+5% +$141K 1.05% 20
2019
Q1 		$3.08M Buy
+40,155
New +$2.23M 0.94% 23

Other funds holding GH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aristotle Atlantic Partners's GH Position: Q1 2026 in Review

Aristotle Atlantic Partners reduced its Guardant Health (GH) stake by 9.9% in Q1 2026, selling an estimated $4.91M and leaving 445,530 shares worth $41.2M. The position accounts for 1.93% of the portfolio, ranked #15.

Aristotle Atlantic Partners first reported a position in GH in Q1 2019 and has held it in 29 quarters since. The position peaked at $57.7M in Q3 2025. 481 funds tracked by Wall St. Rank hold GH as of Q1 2026.

  • Aristotle Atlantic Partners held 445,530 shares of Guardant Health worth $41.2M as of Q1 2026.
  • Aristotle Atlantic Partners sold 48,856 Guardant Health shares in Q1 2026, an estimated $4.91M.
  • Guardant Health made up 1.93% of Aristotle Atlantic Partners's portfolio in Q1 2026, its #15 holding.
  • Aristotle Atlantic Partners first reported a position in Guardant Health in Q1 2019 and has held it in 29 quarters since.
  • Aristotle Atlantic Partners's Guardant Health position peaked at $57.7M in Q3 2025.
  • 481 funds tracked by Wall St. Rank held Guardant Health as of Q1 2026.

Based on Aristotle Atlantic Partners's 13F filing for Q1 2026, filed 15 May 2026.